Larimar submits BLA for nomlabofusp, Q2 cash $156.3M

Larimar Therapeutics submitted the first module of a rolling BLA for nomlabofusp in June and reported $156.3 million in cash as of June 30, 2026, extending their runway into Q3 2027. The submission supports their bid to develop the first therapy for Friedreich's ataxia.